BofA initiates coverage on IMMX with a Buy rating and $27 price target. RBC starts PRAX with Outperform ($449 PT), while Cantor begins coverage on RNA. Morgan Stanley downgrades ENGN to Underweight.
enGene is reducing its workforce by ~50% and has stopped patient enrollment in three additional LEGEND trial cohorts to preserve cash while focusing on its pivotal data and planned BLA filing.
enGene bladder cancer drug shows good safety and early response, but weak long-term results; stock drops ~66% after update.
Mizuho and Jefferies initiate coverage on Pulse Biosciences and enGene, highlighting growth potential, strong clinical data, and upcoming catalysts in biotech.
Raymond James upgrades enGene to Strong Buy with $27 target as detalimogene shows 62% complete response rate in bladder cancer trial with excellent tolerability.
